Major Pharma News May to July 2018 Highlights Pill

Competition In Medicines E – Commerce
Flipkart, Amazon, BigBasket and Swiggy are all in exploratory talks to acquire, partner or invest in online pharma players including MedPlus, 1mg, Medlife, PharmEasy and Myra. The online medicine-delivery category represents a significant strategic opportunity given easing regulations and its potential to drive repeat orders.
Govt proposes over Rs 460 crore support for development of pharmaceutical Industry
The government has proposed over Rs 460 crore support for th development of pharmaceuticals industry with an aim to reduce cost of bulk drugs and medical devices through up of common facility centres and to help SMEs upgrade technology. Announcing guidelines for five sub-schemes under the development programme objective is to reduce cost of production by 20-25 per in bulk drug parks. The scheme termed as development of common facility of centre for medical device (DCFCMD)
Telangana to set up hub for biotech, pharma sector
The Telangana government will set up a biotech and pharma facility, B-Hub, with an investment of ₹60 crore.
The state-of-the-art Hub, which will have a scale-up manufacturing facility for biopharma-based R&D, will come up at the Genome Valley here.
Opportunity For Indian Pharma in China
The Chinese government is said to have assured its Indian counterpart of expediting the process of drug approvals in less than 12 months, a major impediment for Indian drug makers entry to world’s second largest pharmaceutical market.Currently it takes around five years to get an approval in China, while Indian drug regulator approves drug product within 3-6 months.
The China Food and Drug Administration, or CFDA is very clear about expediting entry of Indian generic pharmaceuticals.
Gujarat seems poised to regain its lost share in India’s pharmaceutical production with firms choosing the state over tax havens for setting up new manufacturing facilities thanks to GST. GST has significantly narrowed the manufacturing cost difference between regions that offer incentives and other states like Gujarat.
China Vaccines Scandal Hit Stocks Chinese pharmaceutical stocks plunged, as an unfolding safety scandal over the nation’s vaccines reminded investors of the series of food and product recalls from a decade ago that decimated China’s reputation as the world’s factory – an industry damage that and took years to repair.
Sun Pharma gets USFDA nod for prostate cancer drug
Drug major Sun Pharmaceutical Industries subsidiary has received approval from the US health regulator for YONSA, used for treatment of a form of prostate cancer. Sun Pharma had acquired YONSA from Churchill Pharmaceuticals and will commercialise the drug in the US.
Sun Pharma gets USFDA nod for cancer treatment injection
Drug major Sun Pharmaceutical Industries today said it has received approval from the US health regulator for its INFUGEM injection used for treatment of cancer.
Pharma sector may post 17% revenue growth in June quarter
The pharmaceutical industry is likely to report a 17 per cent revenue growth in the June quarter, driven by strong domestic growth and currency tailwinds Edelweiss Securities said in its report
Govt panel Recommends banning 343 fixed dose combinations: 
The Drug Technical Advisory Board (DTAB) sub-committee has come down hard on pharmaceutical companies manufacturing Fixed-Dose Combinations (FDCs) of certain drugs, after reviewing them over the past seven months.
The sub-committee said of the 349 FDCs under review, 343 of them must be banned. “For most FDCs, their use would lead to unnecessary overuse, and the patients would be exposed to risk of multiple ingredients when one would suffice.
Sun Pharma launches generic Glumetza
Sun Pharma enters in a competitive Metformin market . The drug size has shrunk by 63% since Sun Pharma received the approval in 2016.
Sun pharma’s US subsidiary DUSA pharmaceuticals  filed a law suit against German drug maker Biofrontera for patent infringement, trade secret misappropriation and tortious interference claims in an on going patent infringement suit.
Aurobindo Pharma gets approval for Ibuprofen capsules. Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Ibuprofen capsules, used to relieve pain and reduce fever.
Aurobindo Pharma to acquire Apotex International Inc. Aurobindo Pharma Ltd has signed a pact to acquire the commercial operations and certain supporting infrastructure of Canadian pharmaceutical firm Apotex International Inc. in five European countries for €74 million ($86.5 million).
Aptar Pharma has partnered with Propeller Health
In a move that signals the pharmaceutical industry’s growing interest in digital therapeutics, Aptar Pharma has partnered with Propeller Health, a pioneer in this burgeoning field. The company, a division of Aptar Group, is one the biggest makers of drug delivery devices. Aptar and Propeller will connect those devices via sensors to Propeller’s software to manage respiratory diseases, opioid addiction and pain, among other areas.
Alembic Share rises
Shares of Alembic Pharmaceuticals are locked in upper circuit of 20% at Rs 522 per share on the BSE after the company said that it has received approval from the US drug health regulator for anti-depression ,. Bupropion hydrochloride tablets USP, 75 mg and 100 mg.
Also Drug firm Alembic Pharmaceuticals received approval from the US health regulator for its Doxycycline Hyclate capsules used for treatment of wide variety of bacterial infections.
Glenmark Pharmaceuticals Inc., USA has been granted final approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packe by the United States Food & Drug Administration (USFDA)
Aurobindo Pharma Limited got the approval  to manufacture and market Bivalirudin injection of 250 mg/vial by the US Food and Drug Administration (USFDA), the drug was a generic equivalent to the Angiomax injection.
Drug firm Aurobindo Pharma has received final approval to manufacture and market Azithromycin tablets from the USFDA , used for the treatment of patients with mild to moderate infections, in the US market.
Natco Pharma has launched fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.
NIPER PhD Student Deepika Kathuria awarded Newton Bhabha Fellowship. She is working in medicinal Chemistry department on new molecules for treatment of Kala Azar. During fellowship , she will stay at university of Sheffield and learn advanced techniques of cell culture, and development of Anti Alzhiemer agents.

Leave a Comment

Your email address will not be published. Required fields are marked *

Language »